Clinical Trial Update: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial of sorafenib tosylate in children and young patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma, or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Papillary Thyroid Cancer
• Rhabdomyosarcoma
• Wilms Tumor

Drugs mentioned

• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-05-15